Theranos | Start Up Pitch Deck | 24 slides — playbook

Theranos | Start Up Pitch Deck | 24 slides

Theranos · 2006-06

arc beats above · slides in the middle · loops below · scroll → 2 LOOPS

Deck intelligence map

4

coverage by narrative range · generated from this deck JSON

Narrative range 9 total

Metadata

Components

Metrics

Tools

Frameworks

Beats

Loops

Problem 2 slides 100% 2/2 slides 100% 2/2 slides · 6 hits

— 0/2 slides

— 0/2 slides

50% 1/2 slides 100% 2/2 slides 100% 2/2 slides Solution 4 slides 100% 4/4 slides 100% 4/4 slides · 16 hits

— 0/4 slides

— 0/4 slides

25% 1/4 slides 100% 4/4 slides

— 0/4 slides

Market Size 2 slides 100% 2/2 slides 100% 2/2 slides · 7 hits

— 0/2 slides

— 0/2 slides

50% 1/2 slides 100% 2/2 slides

— 0/2 slides

Team 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits

— 0/1 slides

— 0/1 slides

— 0/1 slides

100% 1/1 slides

— 0/1 slides

Slide inventory

24

every slide · same image gating as the playbook

01

front_matter

Open slide detail

02

summarize

Open slide detail

03

The slide lists specific deal counts and revenue projections for validation and phase IV stages.show_traction

Open slide detail

04

Includes both executive management and board members.other

Open slide detailBeat · Team

05

The slide features photos of the proprietary hardware and a line chart comparing 'Competitive' vs 'Two Step' assay performance.present_solution

Open slide detail

06

The slide illustrates a proprietary hardware/software stack.present_solution

Open slide detailBeat · Solution

07

The slide uses a hub-and-spoke diagram to show data flow between healthcare stakeholders and a central informatics system.present_solution

Open slide detailBeat · Solution

08

The slide highlights key performance metrics like sample size, assay time, and precision.present_solution

Open slide detailBeat · Solution

09

present_solution

Open slide detailBeat · Solution

10

The slide illustrates a failure case (drug toxicity) to justify the value of the Theranos monitoring system.present_solution

Open slide detail

11

The chart shows a 'Second course (Drug dose reduced)' with three series: dose, drug level, and target.show_traction

Open slide detail

12

The chart shows a comparison between a 'first course' (uncontrolled) and a 'corrected' course where the drug level is managed.present_solution

Open slide detail

13

The chart illustrates a feedback loop: drug dose is reduced when toxicity markers exceed the alert level, successfully bringing toxicity down.present_solution

Open slide detail

14

The slide uses a bulleted list to break down market metrics including total market size, trial volume, and per-trial revenue projections.size_opportunity

Open slide detailBeat · Market Size

15

The slide explicitly notes that academic institutions are excluded from this TAM calculation.size_opportunity

Open slide detailBeat · Market Size

16

present_solution

Open slide detail

17

The slide uses a bulleted list to highlight specific industry failures that the company intends to address.frame_problem

Open slide detailBeat · ProblemLoop · Cost Of Inaction

18

present_solution

Open slide detailBeat · ProblemLoop · Cost Of Inaction

19

present_solution

Open slide detail

20

The slide specifies a split between existing and new investors.plan_implementation

Open slide detailLoop · Quick Win Big Bet

21

Lists specific venture capital firms and individual investors.show_traction

Open slide detailLoop · Quick Win Big Bet

22

The slide uses five distinct scientific charts to demonstrate technical parity or superiority of the Theranos system.compare_peers

Open slide detail

23

This slide illustrates the core technical claim of the Theranos system's calibration and data processing workflow.present_solution

Open slide detail

24

This is a closing/filler slide for a pitch deck template.other

Open slide detail